Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors

Oraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P‐glycoprotein inhibitor encequidar methanesulfonate monohydrate (formerly named HM30181A), which allows oral treatment of cancers that would otherwise be treated with intravenous paclitaxel. He...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jimmy, Jackson, Christopher G. C. A., Deva, Sanjeev, Hung, Tak, Clarke, Katriona, Segelov, Eva, Chao, Tsu‐Yi, Dai, Ming‐Shen, Yeh, Hsien‐Tang, Ma, Wen Wee, Kramer, Douglas, Chan, Wing‐Kai, Kwan, Rudolf, Cutler, David, Zhi, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286714/
https://www.ncbi.nlm.nih.gov/pubmed/35470967
http://dx.doi.org/10.1002/psp4.12799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286714/
https://www.ncbi.nlm.nih.gov/pubmed/35470967
http://dx.doi.org/10.1002/psp4.12799

Ejemplares similares